The Conversation (0)
MariMed announced an exclusive global licensing agreement with Vitiprints for its proprietary technology and worldwide production and distribution rights.
MariMed (OTCQB:MRMD) announced an exclusive global licensing agreement with Vitiprints for its proprietary technology and worldwide production and distribution rights.
As quoted in the press release:
“Our exclusive agreement with Vitiprints puts MariMed on the forefront of precision-dosed branded cannabis products and technology that will, above all, delight consumers with a revolutionary product category and experience,” said Robert Fireman, MariMed CEO. “This innovative technology enables creation of infused cannabis products which can be specifically designed for dosage, flavor, and supplements to achieve the desired effect or result. These products can be manufactured at speeds and efficiencies that will create cost savings for producers and consumers, while generating significant incremental revenue streams for MariMed from sales and sublicensing agreements.”
The patent-pending Vitiprints technology – a first for the cannabis industry — is already under development for consumer consumption in other industries. For MariMed, the platform combines multiple layers of marijuana ingredients, such as cannabinoids, terpenes, graphic design elements and other ingredients, into a paper-thin low-calorie product that is delivered sublingually, transdermally, or by drinking when dissolved in any liquid. The product can be used to create its own beverage or tea or as an enhancement to other beverages. Achieving total control over the ingredient layers, the platform further enables precision dosing and fast absorption, without the additional fillers commonly found in cannabis and nutraceutical products. This product transports easily in purses, pockets, and wallets with seamless discretion and convenience.
